Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Gamida Cell (GMDAQ)
OTHER OTC:GMDAQ
Gamida Cell (GMDAQ) Stock Price & Analysis
1,423 Followers
GMDAQ Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range<$0.01 - $2.51
Previous Close$0.02
Volume595.82K
Average Volume (3M)9.47M
Market Cap
$2.33M
Enterprise Value$28.33M
Total Cash (Recent Filing)$60.43M
Total Debt (Recent Filing)$85.93M
Price to Earnings (P/E)>-0.1
Beta1.16
Next Earnings
May 07, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.65
Shares Outstanding154,050,953
10 Day Avg. Volume1,541,072
30 Day Avg. Volume9,465,088
Standard Deviation0.29
R-Squared0.03
Alpha-0.05
Financial Highlights & Ratios
Price to Book (P/B)13.19
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.10
Enterprise Value/Gross Profit-22.07
Enterprise Value/Ebitda-0.22
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
Bulls Say, Bears Say
Bulls Say
Competitive AdvantageOmisirge is praised for its rapid hematopoietic recovery and lower risks for GvHD, which are significant advantages in cell therapy.
Growth StrategyIn 2024, the company aims to onboard 20 new transplant centers with more revenue-generating units expected.
Product LaunchThe early launch metrics for Omisirge have been impressive, with six revenue-generating units delivered and significant reimbursement access established.
Bears Say
Company StrategyStepping to the sidelines as Gamida explores strategic alternatives; rating lowered to Market Perform from Market Outperform.
Product CommercializationCommercial efforts for Omisirge remain resource constrained, adding to the uncertainty of the company's future resources.
Valuation AdjustmentIncreased the discount rate in the valuation from 20% to 50%, resulting in a fair value of approximately $0.43/share.
---
Ownership Overview
6.14% Insiders
4.56% Mutual Funds
0.18% Other Institutional Investors
89.12% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
GMDAQ FAQ
What was Gamida Cell’s price range in the past 12 months?
Gamida Cell lowest stock price was <$0.01 and its highest was $2.51 in the past 12 months.
What is Gamida Cell’s market cap?
Currently, no data Available
When is Gamida Cell’s upcoming earnings report date?
Gamida Cell’s upcoming earnings report date is May 07, 2024 which is in 6 days.
How were Gamida Cell’s earnings last quarter?
Gamida Cell released its earnings results on Mar 27, 2024. The company reported $0.02 earnings per share for the quarter, beating the consensus estimate of -$0.152 by $0.172.
Is Gamida Cell overvalued?
According to Wall Street analysts Gamida Cell’s price is currently Overvalued.
Does Gamida Cell pay dividends?
Gamida Cell does not currently pay dividends.
What is Gamida Cell’s EPS estimate?
Gamida Cell’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Gamida Cell have?
Gamida Cell has 154,050,950 shares outstanding.
What happened to Gamida Cell’s price movement after its last earnings report?
Gamida Cell reported an EPS of $0.02 in its last earnings report, beating expectations of -$0.152. Following the earnings report the stock price went down -82.353%.
Which hedge fund is a major shareholder of Gamida Cell?
Among the largest hedge funds holding Gamida Cell’s share is ARK Investment Management LLC. It holds Gamida Cell’s shares valued at 884K.
---
Gamida Cell Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
― (―)
― (―)
Hedge Fund Trend
Increased
By 724.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.6%
Last 30 Days ▼ 1.7%
Last 30 Days ▼ 1.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-98.83%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-18.10%
Trailing 12-Months
Company Description
Gamida Cell
Gamida Cell Ltd. is a clinical stage biopharmaceutical company engaging in the development of cell therapies to cure blood cancer and rare serious hematologic diseases. The company was founded by Tony Peled and Menashe Levy in 1998 and is headquartered in Jerusalem, Israel.
---
GMDAQ Stock 12 Months Forecast
Average Price Target
―Technical Analysis
Gritstone Oncology
―
Corbus Pharmaceuticals
―
Karyopharm Therapeutics
―
Madrigal Pharmaceuticals
―
Best Analysts Covering GMDAQ
1 Year
1 Year Success Rate
4/20 ratings generated profit
1 Year Average Return
-31.13%
reiterated a buy rating 12 months ago
Copying Mark Breidenbach's trades and holding each position for 1 Year would result in 20.00% of your transactions generating a profit, with an average return of -31.13% per trade.
---